Phagenesis Ltd Secures $33M in Funding to Revolutionize Dysphagia Treatment

Phagenesis Ltd is thrilled to announce a significant milestone in our journey towards revolutionizing dysphagia treatment with the successful closure of a $33 million funding round. This capital injection will allow us to accelerate the development and adoption of our groundbreaking product, the Phagenyx, which employs Pharyngeal Electrical Stimulation (PES) technology to restore swallowing function in individuals suffering from dysphagia. Affecting millions worldwide, dysphagia can severely hinder one’s quality of life, making it critical to provide effective, safe, and non-invasive solutions. The Phagenyx device has been meticulously validated through clinical trials, showcasing its ability to enhance swallowing capabilities, providing hope and independence back to patients. The funding will be allocated toward expanding our clinical research efforts, increasing our manufacturing capabilities, and enhancing our collaborative initiatives with healthcare professionals to ensure that the Phagenyx meets the highest standards of efficacy and safety. As we continue to push the boundaries in dysphagia treatment, we remain committed to our mission of improving the lives of patients worldwide, allowing them to once again enjoy the simple pleasure of mealtime. We express our deepest gratitude to our investors for believing in our vision, and we invite everyone to follow our LinkedIn page to stay updated on our progress as we pave the way for a brighter future in dysphagia care. Together, we can make a meaningful difference for millions affected by this challenging condition.